
Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID
DIFICLIRTM (fidaxomicin) is now recommended as first-line CDI treatment in both European and U.S. guidelines1,2 Significantly fewer patients in the fidaxomicin group than the vancomycin […]






